alleen voor onderzoeksdoeleinden

Perifosine Akt remmer

Name: Perifosine
Brand: Selleck Chemicals
SKU: S1037
Rating: 5 (168 reviews)

Cat.nr.S1037

Perifosine is een nieuwe Akt-remmer met een IC50 van 4,7 μM in MM.1S-cellen, die zich richt op het pleckstrine-homologiedomein van Akt. Fase 3.

Perifosine Akt remmer Chemical Structure

Chemische structuur

Molecuulgewicht: 461.66

Spring naar

Kwaliteitscontrole

Batch: Zuiverheid: >97%

Geciteerd in Nature Medicine voor zijn topkwaliteit
COA
NMR
Microanalyse

Waarom microanalyse?
Gegevensblad
SDS

Geciteerd in Nature Medicine voor zijn topkwaliteit
COA
NMR
Gegevensblad
SDS

Geciteerd in Nature Medicine voor zijn topkwaliteit
COA
NMR
Gegevensblad
SDS

Geciteerd in Nature Medicine voor zijn topkwaliteit
COA
NMR
Gegevensblad
SDS

Geciteerd in Nature Medicine voor zijn topkwaliteit
COA
NMR
Gegevensblad
SDS

Gerelateerde doelwitten	PI3K mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK
Overig Akt Inhibitoren	SC79 AZD5363 (Capivasertib) MK-2206 Dihydrochloride Ipatasertib (GDC-0068) GSK690693 Triciribine (API-2) Afuresertib (GSK2110183) CCT128930 A-674563 HCl Akti-1/2

Celkweek, behandeling & werkzame concentratie

Cellijnen	Assaytype	Concentratie	Incubatietijd	Activiteitsbeschrijving	PMID
HL-60	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
MOLM	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
OCI	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
BJAB	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
MAVER	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
SKW6.4	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
HL-60	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
MOLM	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
OCI	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
BJAB	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
MAVER	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
SKW6.4	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
A2780cis	Growth Inhibition Assay	0-20 μM	48/72 h	IC50 = 6 μm	20405296
A2780	Growth Inhibition Assay	0-20 μM	48/72 h	IC50 = 3 μm	20405296
SKOV3	Growth Inhibition Assay	0-40 μM	72 h	IC50~30 μM, inhibits cell growth in a dose dependent manner	20405296
PA-1	Growth Inhibition Assay	0-40 μM	72 h	IC50~25 μM, inhibits cell growth in a dose dependent manner	20405296
OAW-42	Growth Inhibition Assay	0-40 μM	72 h	IC50~10 μM, inhibits cell growth in a dose dependent manner	20405296
Bel-7402	Apoptosis Asssay	5/10/20 μM	24/48 h	induces apoptosis at the long-time exposure	20842425
HepG2	Apoptosis Asssay	5/10/20 μM	24/48 h	induces apoptosis at the long-time exposure	20842425
Bel-7402	Function Assay	5/10/20 μM	24 h	results in the accumulation of cell number in the G2/M phase	20842425
HepG2	Function Assay	5/10/20 μM	24 h	results in the accumulation of cell number in the G2/M phase	20842425
Bel-7402	Growth Inhibition Assay	5/10/20/40 μM	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
HepG2	Growth Inhibition Assay	5/10/20/40 μM	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
CWR22RV1	Function Assay	5 μM	24 h	reduced phosphorylation of Akt significantly	21496273
CWR22RV1	Apoptosis Asssay	10 μM	24 h	enhances radiation induced apoptosis	21496273
CWR22RV1	Cell Viability Assay	10 μM	24 h	increases sensitivity of human CWR22RV1 cells to radiation	21496273
A498	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
769-P	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
CAKI-1	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
786-O	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
786-0	Growth Inhibition Assay	0-40 μM	72 h	IC50~5 μM	21644050
769-P	Growth Inhibition Assay	0-40 μM	72 h	IC50~5-10 μM	21644050
CAKI-1	Growth Inhibition Assay	0-40 μM	72 h	IC50~10 μM	21644050
A498	Growth Inhibition Assay	0-40 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
HT-29	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
A2780	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
SKOV3	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
CaOV3	Cell Viability Assay	1/5/10 μM	48 h	decreases cell viability in a dose dependent manner cotreated with paclitaxel	21775054
OCUT1	Function Assay	3 μm	24 h	causes a dramatic increase in G2/M phase	22090271
K1	Growth Inhibition Assay	0.1-3 μM	5 d	inhibits cell growth in a dose dependent manner	22090271
OCUT1	Growth Inhibition Assay	0.1-3 μM	5 d	inhibits cell growth in a dose dependent manner	22090271
K562	Function Assay	20 μM	48 h	induces autophagy	22407228
HL-60	Function Assay	2.5/5/10 μM	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
Kasumi-1	Function Assay	2.5/5/10 μM	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
HL-60	Function Assay	2.5/5/10 μM	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
Kasumi-1	Function Assay	2.5/5/10 μM	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
HL-60	Apoptosis Asssay	10 μM	24 h	induces apoptosis	22407228
Kasumi-1	Apoptosis Asssay	10 μM	24 h	induces apoptosis	22407228
HL-60	Cell Viability Assay	0-20 μM	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
Kasumi-1	Cell Viability Assay	0-20 μM	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
BON1	Function Assay	7.5/10 μM	8 h	decreases the expression of the anti-apoptotic proteins BCL2 and Bcl-XL	22499437
BON1	Apoptosis Asssay	0-10 μM	24 h	induces apoptosis dose dependently	22499437
BON1	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
GOT1	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
NCI-H727	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
MCAS	Growth Inhibition Assay			IC50=12.5 μM	23877012
A2780S	Growth Inhibition Assay			IC50=14.5 μM	23877012
OVCAR5	Growth Inhibition Assay			IC50=6.7 μM	23877012
A2780CP	Growth Inhibition Assay			IC50=7.6 μM	23877012
HeyA8	Growth Inhibition Assay			IC50=24.3 μM	23877012
OVCAR8	Growth Inhibition Assay			IC50=31.1 μM	23877012
M41R	Growth Inhibition Assay			IC50=19.8 μM	23877012
M41	Growth Inhibition Assay			IC50=24.7 μM	23877012
TykNuR	Growth Inhibition Assay			IC50=5.5 μM	23877012
TykNu	Growth Inhibition Assay			IC50=3.5 μM	23877012
MGC803	Function Assay	0.75/10 μM	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
SGC7901	Function Assay	0.75/10 μM	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
U87MG	Cell Viability Assay	0-25 μM	24-96 h	decreases cell viability in both dose and time dependent manner	24065522
AsPC-1	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
MIA	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
PANC-1	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
AsPC-1	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
MIA	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
PANC-1	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
Ema	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=58.7 μM	24881508
UL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=7.01 μM	24881508
CLBL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=33.0 μM	24881508
GL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=9.91 μM	24881508
MDA-MB-231	Growth Inhibition Assay	0-10 μM	48 h	EC50=1.13 ± 0.07 μM	25293576
HCC1806	Growth Inhibition Assay	0-10 μM	48 h	EC50=2.84 ± 0.07 μM	25293576
RMG2	Apoptosis Asssay	30 μM	24 h	induces apoptosis	25519148
RMG1	Apoptosis Asssay	30 μM	24 h	induces apoptosis	25519148
A2780	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
SKOV3	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
OVISE	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
RMG2	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
HAC2	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
KOC7C	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
RMG2	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
RMG1	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
H460	Function Assay	3 μM	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
A549	Function Assay	3 μM	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
H460	Function Assay	3 μM	8 h	blocks AKT activation	25697899
A549	Function Assay	3 μM	8 h	blocks AKT activation	25697899
H460	Apoptosis Asssay	1/3 μM	48 h	induces apoptosis	25697899
A549	Apoptosis Asssay	1/3 μM	48 h	induces apoptosis	25697899
H460	Growth Inhibition Assay	0.3-10 μM	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
A549	Growth Inhibition Assay	0.3-10 μM	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
U-87 MG	Growth Inhibition Assay	20/40 μM	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
HepG2	Growth Inhibition Assay	20/40 μM	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
U-87 MG	Function Assay	20 μM	6/24 h	increases the autophagic flux at 6 h while inhibits this flux at 24h	25934232
HepG2	Function Assay	20 μM	6/24 h	decreases LC3-II degradation from 6 h	25934232
U-87 MG	Function Assay	20 μM	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
HepG2	Function Assay	20 μM	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
U-87 MG	Function Assay	20 μM	24 h	increases double-membrane bound structures	25934232
HepG2	Function Assay	20 μM	24 h	produces an intense cytoplasmic vacuolization corresponding to a notable dilatation of the ER cisterns	25934232
T24 BC	Apoptosis Asssay	2.5 μM	24 h	sensitizes BC cells to sorafenib-induced apoptotic	26097873
T24 BC	Cell Viability Assay	0.5/1/2.5 μM	24 h	enhances sorafenib-induced cell viability decrease	26097873
T24 BC	Function Assay	0.5/1/2.5 μM	3 h	reduces the basal CB tyrosine phosphorylation levels in a dose-dependent manner	26097873
RBL2H3	Function assay			Toxicity in rat RBL2H3 cells, MTD=25μM	20153565
PC3	Growth inhibition assay			Growth inhibition of human PC3 cells by sulforhodamine B assay, GI50=0.44μM	21543141
NUGC3	Growth inhibition assay			Growth inhibition of human NUGC3 cells by sulforhodamine B assay, GI50=0.54μM	21543141
HCT15	Growth inhibition assay			Growth inhibition of human HCT15 cells by sulforhodamine B assay, GI50=1.25μM	21543141
MDA-MB-231	Growth inhibition assay			Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay, GI50=2.86μM	21543141
NCI-H23	Growth inhibition assay			Growth inhibition of human NCI-H23 cells by sulforhodamine B assay, GI50=4.21μM	21543141
ACHN	Growth inhibition assay			Growth inhibition of human ACHN cells by sulforhodamine B assay, GI50=4.56μM	21543141
A549	Function assay		30 mins	Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA, IC50=5.3μM	22138309
A549	Cytotoxicity assay		24 hrs	Cytotoxicity against human A549 cells after 24 hrs by FACS analysis, IC50=7μM	22138309
KATO III	Cytotoxicity assay		24 hrs	Cytotoxicity against human KATO III cells after 24 hrs by FACS analysis, IC50=12.8μM	22138309
MCF7	Cytotoxicity assay		24 hrs	Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis, IC50=13.3μM	22138309
PC3	Growth inhibition assay			Growth inhibition of human PC3 cells by SRB assay, GI50=0.44μM	23266181
NUGC3	Growth inhibition assay			Growth inhibition of human NUGC3 cells by SRB assay, GI50=0.54μM	23266181
HCT15	Growth inhibition assay			Growth inhibition of human HCT15 cells by SRB assay, GI50=1.25μM	23266181
MDA-MB-231	Growth inhibition assay			Growth inhibition of human MDA-MB-231 cells by SRB assay, GI50=2.86μM	23266181
NCI-H23	Growth inhibition assay			Growth inhibition of human NCI-H23 cells by SRB assay, GI50=4.21μM	23266181
ACHN	Growth inhibition assay			Growth inhibition of human ACHN cells by SRB assay, GI50=4.56μM	23266181
A549	Function assay		2 hrs	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA, IC50=5.3μM	23415083
A549	Cytotoxicity assay			Cytotoxicity against human A549 cells by flow cytometric analysis, IC50=7μM	23415083
KATO III	Cytotoxicity assay			Cytotoxicity against human KATO III cells by flow cytometric analysis, IC50=12.8μM	23415083
MCF7	Cytotoxicity assay			Cytotoxicity against human MCF7 cells by flow cytometric analysis, IC50=13.3μM	23415083
PC3	Antiproliferative assay			Antiproliferative activity against human PC3 cells by SRB assay, GI50=0.44μM	23567950
NUGC3	Antiproliferative assay			Antiproliferative activity against human NUGC3 cells by SRB assay, GI50=0.54μM	23567950
HCT15	Antiproliferative assay			Antiproliferative activity against human HCT15 cells by SRB assay, GI50=1.25μM	23567950
MDA-MB-231	Antiproliferative assay			Antiproliferative activity against human MDA-MB-231 cells by SRB assay, GI50=2.86μM	23567950
NCI-H23	Antiproliferative assay			Antiproliferative activity against human NCI-H23 cells by SRB assay, GI50=4.21μM	23567950
ACHN	Antiproliferative assay			Antiproliferative activity against human ACHN cells by SRB assay, GI50=4.56μM	23567950
PC3	Growth inhibition assay		48 hrs	Growth inhibition of human PC3 cells after 48 hrs by SRB assay, GI50=0.44μM	24095759
NUGC3	Growth inhibition assay		48 hrs	Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay, GI50=0.54μM	24095759
HCT15	Growth inhibition assay		48 hrs	Growth inhibition of human HCT15 cells after 48 hrs by SRB assay, GI50=1.25μM	24095759
MDA-MB-231	Growth inhibition assay		48 hrs	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay, GI50=2.86μM	24095759
NCI-H23	Growth inhibition assay		48 hrs	Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay, GI50=4.21μM	24095759
ACHN	Growth inhibition assay		48 hrs	Growth inhibition of human ACHN cells after 48 hrs by SRB assay, GI50=4.56μM	24095759
A549	Cytotoxicity assay		24 to 72 hrs	Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry, IC50=4.17μM	24900620
Rosetta cells	Function assay			Inhibition of wild-type human P38alpha MAPK expressed in Escherichia coli Rosetta cells, IC50=1.2μM	31274316
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit

Molecuulgewicht	461.66	Formule	C₂₅H₅₂NO₄P	Opslag (vanaf de datum van ontvangst)	3 jaar-20°Cpoeder
CAS-nr.	157716-52-4	SDF downloaden		Opslag van stamoplossingen	1 jaar-80°Cin oplosmiddel 1 maand-20°Cin oplosmiddel
Synoniemen	KRX-0401, NSC639966, D21266			Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

Oplosbaarheid

In vitro
Batch:

Water : 92 mg/mL

Ethanol : 92 mg/mL

DMSO : Insoluble
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Molariteitscalculator

Massa	Concentratie	Volume	Molecuulgewicht
=	×	×

Verdunningscalculator Molecuulgewichtcalculator

In vivo Batch:
Clear solution	water Gevalideerd door Selleck labs. Mocht u aanpassingen aan deze formulering nodig hebben, neem dan contact op met ons verkoopteam voor aangepaste tests.	8.000mg/ml (17.33mM)	Taking the 1 mL working solution as an example, add 8 mg of this product to 1 ml of ddH2O, mix evenly to make it clear, The mixed solution should be used immediately for optimal results.

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

Dosering: mg/kg Gemiddeld gewicht van dieren: g Doseervolume per dier:μL Aantal dieren:

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH₂O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme

Targets/IC₅₀/Ki	Akt (MM.1S cells) 4.7 μM
In vitro	Perifosine ontwikkelt antiproliferatieve eigenschappen met IC50 van 0,6-8,9 μM in geïmmortaliseerde keratinocyten (HaCaT) en plaveiselcelcarcinoomcellen van hoofd en nek. Deze verbinding vermindert de fosforyleringsniveaus van Akt en extracellulair signaal-gereguleerde kinase (Erk) 1/2 sterk, induceert celcyclusarrest in G1 en G2, en veroorzaakt dosisafhankelijke groeiremming van muizengliacellen. Het remt de fosforylering van Akt in MM.1S-cellen volledig. Een recente studie toont aan dat deze chemische stof celcyclusarrest en apoptose induceert in menselijke hepatocellulaire carcinoomcellijnen door blokkering van Akt-fosforylering.
Kinase Assay	Akt kinase assay
Kinase Assay	MM.1S-cellen worden gekweekt in aanwezigheid of afwezigheid van perifosine (5 μM, 6 uur) en vervolgens gestimuleerd met IL-6 (20 ng/mL, 10 minuten). Een in vitro Akt kinase assay wordt vervolgens uitgevoerd met behulp van de Akt Kinase Assay Kit.
In vivo	Perifosine in combinatie vermindert tumorgroei (een PDGF-gedreven gliomagenese) in vivo. De resultaten wijzen erop dat deze verbinding een effectief medicijn is bij gliomen waarin Akt- en Ras-Erk 1/2-routes frequent geactiveerd zijn, en een nieuwe kandidaat kan zijn voor glioombehandeling in de kliniek. Zowel dagelijkse als wekelijkse orale toediening van deze chemische stof vermindert significant de groei van menselijke MM-tumoren en verhoogt de overleving, vergeleken met controledieren die alleen met PBS-drager zijn behandeld. Het induceert trombocytose en leukocytose en verhoogt myelopoëse in muizenmerg en milt, terwijl het apoptose veroorzaakt in myeloomxenotransplantaten.
Referenties	[1] https://pubmed.ncbi.nlm.nih.gov/11888912/ [2] http://www.ncbi.nlm.nih.gov/pubmed?term=16103096 [3] http://www.ncbi.nlm.nih.gov/pubmed?term=16418332%20 [4] https://pubmed.ncbi.nlm.nih.gov/20842425/ [5] https://pubmed.ncbi.nlm.nih.gov/17588472/

Toepassingen

Methoden	Biomarkers	Afbeeldingen	PMID
Western blot	p-AKT / AKT / p-S6K1 / S6K1 PARP p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1 p-PDK1 / p-GSK3α/β / p-S6R		25519148
Growth inhibition assay	Cell viability		28332584

Informatie over klinische proeven

(gegevens van https://clinicaltrials.gov, bijgewerkt op 2024-05-22)

NCT-nummer	Werving	Aandoeningen	Sponsor/medewerkers	Startdatum	Fasen
NCT01224730	Completed	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Technische ondersteuning

Gebruiksaanwijzing

Tel: +1-832-582-8158 Ext:3

Als u nog andere vragen heeft, laat dan een bericht achter.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):